What Chronic Lyme Actually Means

"Chronic Lyme" is not one thing. It is at least four overlapping claims, and most of the public argument is what happens when people on opposite sides of the debate are using the same words to mean different things.

1. Post-Treatment Lyme Disease Syndrome (PTLDS). Recognised by the IDSA — persistent fatigue, pain or cognitive symptoms for >6 months after a documented, treated infection. Cause unknown; further antibiotics not recommended.
2. Persistent infection with viable Borrelia. Demonstrated in animal models (Embers 2012, Hodzic 2014) and supported by in-vitro persister work (Sapi 2011, Feng 2014). Hotly disputed in humans.
3. Untreated or misdiagnosed late-stage Lyme. Patients who never met seropositivity thresholds or were never tested, presenting years later with neurological, cardiac, or rheumatologic disease.
4. Autoimmune / post-infectious sequelae. Borrelia-triggered immune dysregulation that persists after the organism is cleared (Steere's "antibiotic-refractory Lyme arthritis").

“We are almost certainly looking at several different diseases under one banner.”

The IDSA and ILADS each publish guidelines, and they do not agree on diagnosis, treatment duration, or even whether chronic infection is possible. The split is not really about evidence per se — both sides cite peer-reviewed work — but about how to weigh different kinds of evidence:

• IDSA weighs randomised controlled trials of antibiotic retreatment (Klempner, Krupp, Fallon, Berende) — which are largely negative — and concludes additional antibiotics do more harm than good.
• ILADS weighs the same RCTs but notes their narrow patient selection, short antibiotic courses, and absence of combination/persister-targeting drugs, and argues that animal-model and in-vitro persister evidence justifies longer, combination therapy.

The most consequential recent science is the demonstration that Borrelia burgdorferi forms persister and round-body cells that survive doxycycline, ceftriaxone, and amoxicillin in vitro (Sapi 2011;Feng 2014). Embers et al. (2012, 2017) recovered viable spirochetes from rhesus macaques months after a "successful" course of antibiotics. Whether the same persists in human patients is the central unresolved question.

If chronic Lyme is mostly post-infectious immune damage, antibiotic retreatment is futile and the focus should be immunomodulation. If it is mostly viable persister infection, then better combinations, longer courses, and herbal adjuncts are justified. The reason this page exists, and the reason testing matters, is that the same symptoms can mean either — and the only way to know is to look.